Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/12479
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSoran, Atilla-
dc.contributor.authorÖzbaş, Serdar-
dc.contributor.authorÖzçınar, Beyza-
dc.contributor.authorIşık, Arda-
dc.contributor.authorDoğan, Lütfi-
dc.contributor.authorŞenol, Kazım-
dc.contributor.authorDağ, Ahmet-
dc.contributor.authorKaranlık, Hasan-
dc.contributor.authorAytaç, Özgür-
dc.contributor.authorKaradeniz Çakmak, Güldeniz-
dc.contributor.authorDalcı, Kubilay-
dc.contributor.authorDoğan, Mutlu-
dc.contributor.authorSezer, Atakan Y.-
dc.contributor.authorGökgöz, Şehsuvar-
dc.contributor.authorÖzyar, Enis-
dc.contributor.authorSezgin, Efe-
dc.date.accessioned2022-09-26T11:53:53Z-
dc.date.available2022-09-26T11:53:53Z-
dc.date.issued2022-10-
dc.identifier.issn1068-9265-
dc.identifier.urihttps://hdl.handle.net/11147/12479-
dc.identifier.urihttps://doi.org/10.1245/s10434-022-12239-z-
dc.description.abstractBackground: One fourth of early-stage breast cancer cases become metastatic during the follow-up period. Limited metastasis is a metastatic disease condition in which the number of metastatic sites and the extent of the disease both are limited, and the disease is amenable to metastatic intervention. This prospective study aimed to evaluate intervention for limited metastases in the lung, liver, or both. Methods: The study enrolled luminal A/B and/or human epidermal growth factor receptor 2 (HER2)-neu+ patients with operable lung and/or liver metastases in the follow-up assessment after completion of primary breast cancer treatment and patients with a diagnosis of metastasis after 2014. Demographic, clinical, tumor-specific, and metastasis detection-free interval (MDFI) data were collected. Bone metastasis in addition to lung and liver metastases also was included in the analysis. The patients were divided into two groups according to the method of treatment for metastases: systemic therapy alone (ST) group or intervention (IT) group.en_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofAnnals of Surgical Oncologyen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectBreast canceren_US
dc.subjectMetastasisen_US
dc.subjectProtocol MF 14-02en_US
dc.subjectPulmonary metastasesen_US
dc.subjectHepatic metastasesen_US
dc.titleIntervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-Institutional Registry Study-Imet, Protocol Mf 14-02en_US
dc.typeArticleen_US
dc.authorid0000-0002-8000-7485-
dc.institutionauthorSezgin, Efe-
dc.departmentİzmir Institute of Technology. Food Engineeringen_US
dc.identifier.wosWOS:000829723800015-
dc.identifier.scopus2-s2.0-85134762458-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1245/s10434-022-12239-z-
dc.identifier.pmid35876920-
dc.relation.issn1068-9265en_US
dc.description.volume29en_US
dc.description.issue10en_US
dc.description.startpage6327en_US
dc.description.endpage6336en_US
dc.identifier.wosqualityQ1-
dc.identifier.scopusqualityQ2-
item.languageiso639-1en-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
item.cerifentitytypePublications-
crisitem.author.dept03.08. Department of Food Engineering-
Appears in Collections:Food Engineering / Gıda Mühendisliği
PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File Description SizeFormat 
s10434-022-12239-z.pdfArticle (Makale)348.17 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

7
checked on May 16, 2025

WEB OF SCIENCETM
Citations

5
checked on Jun 27, 2025

Page view(s)

366
checked on Jun 16, 2025

Download(s)

112
checked on Jun 16, 2025

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.